09th week of 2015 patent applcation highlights part 46 |
Patent application number | Title | Published |
20150057159 | METHOD TO IDENTIFY ASYMPTOMATIC HIGH-RISK INDIVIDUALS WITH EARLY STAGE LUNG CANCER BY MEANS OF DETECTING miRNAs IN BIOLOGIC FLUIDS - A diagnostic and/or prognostic model of at least 5 serum miRNAs selected among a group of 34 miRNAs that identifies subjects with early stage lung cancer, namely non-small cell lung carcinomas (NSCLCs), in a population of asymptomatic high-risk individuals, with 80% accuracy. The model could also distinguish between benign and malignant lesions and is sensitive enough to capture the disease onset. In addition, the model could also diagnose or confirm a diagnosis of lung cancer in symptomatic patients, and monitor the lung tumor status after treatment with surgery and/or chemotherapy and/or radiotherapy in a subject with such lung cancer. | 2015-02-26 |
20150057160 | PATHOGEN SCREENING - The present invention relates to methods of isolating pathogenic genomes from a clinical sample. | 2015-02-26 |
20150057161 | HIGH-RESOLUTION TRANSCRIPTOME OF HUMAN MACROPHAGES - The invention is based on the finding of specific surface markers for M1-like (classically activated) and M2-like (alternatively activated) macrophages and provides for a method for the identification, characterization and isolation of M1-like and M2-like macrophages based on the abundance of said surface markers and for means for performing such method. | 2015-02-26 |
20150057162 | PEPTIDE ARRAYS - A method is disclosed for identifying a member of a peptide library that interacts with a target molecule in situ, the method including expressing immobilised nucleic acid molecules to produce the peptide library in a way that each member of the peptide library is immobilised on the nucleic acid molecule from which it was expressed; contacting the immobilised peptide library with the target molecule; and detecting an interaction between at least one member of the peptide library and the target molecule. The method further comprises sequencing the plurality of nucleic acid molecules in situ on the solid support, such that the at least one member of the peptide library that interacts with the target molecule can be immediately identified, at least by the sequence of the nucleic acid molecule from which it was expressed, without requiring additional or secondary analysis or characterising procedures in order to identify the useful members of the library. The target molecules may themselves be comprised within a second nucleic acid or peptide library. | 2015-02-26 |
20150057163 | SYSTEMS AND METHODS FOR EPIGENETIC SEQUENCING - The present invention generally relates to microfluidics and/or epigenetic sequencing. In one set of embodiments, cells contained within a plurality of microfluidic droplets are lysed and the DNA (e.g., from nucleosomes) within the droplets are labeled, e.g., with adapters containing an identification sequence. The adapters may also contain other sequences, e.g., restriction sites, primer sites, etc., to assist with later analysis. After labeling with adapters, the DNA from the different cells may be combined and analyzed, e.g., to determine epigenetic information about the cells. For example, the DNA may be separated on the basis of certain modifications (e.g., methylation), and the DNA from the separated nucleosomes may be sequenced using techniques such as chromatin immunoprecipitation (“ChIP”). In some cases, the DNA sequences may also be aligned with genomes, e.g., to determine which portions of the genome were epigenetically modified, e.g., via methylation. | 2015-02-26 |
20150057164 | HIGH THROUGHPUT METHODS FOR FUNCTIONALLY DETERMINING RNA INTERFERENCE EFFICIENCY - Provided is a single construct combining a sequence encoding an RNAi molecule, a sequence encoding a reporter, and a target sequence specific for the RNAi molecule. The construct can be used to determine the potency of the encoded RNAi molecule in a direct and unbiased way. These results can be used to inform the design of potent RNAi molecules of various types and can be extended to several other applications, including: (1) generation of tiled libraries comprising every possible RNAi molecule-encoding sequence for a given gene target; (2) large-scale parallel validation of RNAi molecules targeting many genes to generate validated RNAi molecule-encoding libraries; (3) experimental comparison of design algorithms and strategies; and (4) investigation of RNAi biology in target site mutagenesis assays by screening pools containing single nucleotide changes in target sites and/or in the RNAi molecule to identify the most relevant sequence characteristics of potent RNAi-target site predictions. | 2015-02-26 |
20150057165 | MICRORNA AND USE THEREOF IN IDENTIFICATION OF B CELL MALIGNANCIES - Disclosed are nucleic acid sequences, including microRNA sequences and cDNA sequences, as well as vectors, DNA libraries, microarrays, and recombinant cells comprising the nucleic acid sequences described herein. Methods of determining the B cell stage from which a B cell malignancy is derived. Methods of identifying B cell malignancies are also provided. Methods of diagnosing B cell malignancies are provided. Such methods comprise, in certain embodiments, detecting one or more microRNAs or cDNAs as disclosed herein. | 2015-02-26 |
20150057166 | METHOD FOR ANALYZING THE THREE DIMENSIONAL STRUCTURE OF A GPCR - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a family C G-protein coupled receptor (GPCR), wherein the first portion comprises the TM1, TM2 and TM3, regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, wherein the second portion comprises the TM4, TM5 TM6 and TM7 regions of the GPCR. | 2015-02-26 |
20150057167 | SYSTEM, METHOD, AND PRODUCT FOR IMAGING PROBE ARRAYS WITH SMALL FEATURE SIZES - An embodiment of a method for resolving features on a probe array is described that, comprises acquiring a plurality of micro-shifted images of a region of a probe array; reconstructing an image of the probe array using the micro-shifted images; and deriving intensity values for one or more probe features disposed on the probe array from the reconstructed image. | 2015-02-26 |
20150057168 | Primers for Detecting Serotypes of Shigella Flexneri and Multiplex Amplifications Using the Same - The present inventions relates to primers for identifying | 2015-02-26 |
20150057169 | Biomarkers for Head-and-Neck Cancers and Precancers - The invention provides markers and methods for detecting head-and-neck precancers, (including OPLs), cancers and related disease conditions in a subject. The invention also provides localization and imaging methods for head-and-neck precancers (including OPLs) and cancers, along with kits for carrying out methods of the invention. The invention further provides therapeutic applications for head-and-neck precancers (including OPLs) and cancers which employ head-and-neck precancer and cancer markers, polynucleotides encoding the markers, and binding agents for the markers. | 2015-02-26 |
20150057170 | METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS - Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals. | 2015-02-26 |
20150057171 | OLIGONUCLEOTIDES AND METHODS FOR DETERMINING A PREDISPOSITION TO SOFT TISSUE INJURIES - A method of determining in a subject a predisposition to, or increased risk for, developing a tendon, ligament, or other soft tissue injury or pathology, the method comprising the step of screening the subject for the presence of at least one polymorphism in at least one gene selected from the group comprising: a) the collagen V gene COL5A1; wherein the COL5A1 gene is rs71746744, rs16399 and/or rs1134170 within the 3′-untranslated region (UTR) of the alpha 1 chain of the COL5A1 gene; b) the MIR608 gene which encodes a miRNA which binds to a recognition sequence within the 3′-UTR of the collagen V gene COL5A1; and c) the CASP8 gene; wherein the presence of the polymorphism is indicative of a predisposition to, or increased risk for, developing a musculoskeletal soft tissue injury in the subject. | 2015-02-26 |
20150057172 | REAL-TIME PCR DETECTION OF MYCOBACTERIUM TUBERCULOSIS COMPLEX - The present invention relates to assays, diagnostic kits and methods for the simultaneous real-time PCR detection of bacteria belonging to the MTR and/or | 2015-02-26 |
20150057173 | METHODS FOR DETERMINING THE TROPISM AND RECEPTOR USAGE OF A VIRUS, IN PARTICULAR HIV, IN BODY SAMPLES TAKEN FROM THE CIRCULATION - The present invention relates to microarrays, sets of primers and methods for determining the co-receptor usage of a virus, in particular whether HIV uses CXCR4 or CCR5 as co-receptor. The methods and compositions of the invention are based on microRNA analysis. The invention can be used to determine virus tropism in any species or organism that expresses microRNAs, particularly in human beings. | 2015-02-26 |
20150057174 | DIFFERENTIAL DIAGNOSTIC METHOD AND KIT FOR INFECTIOUS AND PARASITIC DISEASES, USING FLOW CYTOMETRY - The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analysing the reactivity profile of IgG1 to the biological agents. The present invention further relates to a diagnostic kit. | 2015-02-26 |
20150057175 | METHOD FOR MONITORING HIV SPECIFIC T CELL RESPONSES - The invention relates to a method and a diagnostic kit for monitoring HIV specific T cell responses and identifying subjects capable of controlling HIV progression or preventing HIV infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a vastly larger set of effector functions than standard assays. The method is also suitable to detect T cell responses of any desirable cytokine or combination of cytokines to any pathogen | 2015-02-26 |
20150057176 | CELLULAR MARKERS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE AND FOR ALZHEIMER'S DISEASE PROGRESSION - The present invention provides methods for early diagnosis of Alzheimer's disease and for determining the efficacy of a treatment for Alzheimer's disease in an Alzheimer's patient, i.e., monitoring Alzheimer's disease progression, utilizing cellular blood markers; as well as kits for carrying out these methods. | 2015-02-26 |
20150057177 | METHODS FOR DETERMINING A BREAST CANCER-ASSOCIATED DISEASE STATE AND ARRAYS FOR USE IN THE METHODS - The present invention provides a method for determining a breast cancer-associated disease state comprising the steps of: a) providing a sample to be tested; and b) determining a biomarker signature of the test sample by measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in Table 1; wherein the presence and/or amount in the test sample of the one or more biomarker selected from the group defined in Table 1 is indicative of the breast cancer-associated disease state. The invention further provides arrays and kits fir use in the same. | 2015-02-26 |
20150057178 | SIGNAL ENCODING AND DECODING IN MULTIPLEXED BIOCHEMICAL ASSAYS - This disclosure provides methods, systems, compositions, and kits for the multiplexed detection of a plurality of analytes in a sample. In some examples, this disclosure provides methods, systems, compositions, and kits wherein multiple analytes may be detected in a single sample volume by acquiring a cumulative measurement or measurements of at least one quantifiable component of a signal. In some cases, additional components of a signal, or additional signals (or components thereof) are also quantified. Each signal or component of a signal may be used to construct a coding scheme which can then be used to determine the presence or absence of any analyte. | 2015-02-26 |
20150057179 | Methods and Compositions for hte Diagnosis and Treatment of Thyroid Cancer - Methods for detecting thyroid cancer or thyroid cancer status in a subject are described comprising measuring novel markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for thyroid cancer, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for thyroid cancer employing the novel markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 2015-02-26 |
20150057180 | Methods and Kits for Analyzing Biomarkers in a Signal Transduction Pathway - Provided are methods and kits for analyzing biomarkers in one or more signal transduction pathways in a cell. In some embodiments, the methods and kits of the invention permit simultaneous analysis of more than one biomarker and/or more than one signal transduction pathway. In some embodiments, the invention provides methods for detecting whether a cell treated with an agent targeting a targeted biomarker is responding to the agent, or whether the cell is developing resistance to the agent. In some embodiments, the invention provides methods for determining which biomarker to target in a diseased or damaged cell, or which pathway an agent is targeting in an agent-treated cell. The invention provides kits for carrying out the described methods. | 2015-02-26 |
20150057181 | MICRORNA SIGNATURES INDICATIVE OF IMMUNOMODULATING THERAPY FOR MULTIPLE SCLEROSIS - The present invention provides methods, systems, and kits for evaluating multiple sclerosis (MS) in a patient. Particularly, the invention provides convenient miRNA-based tests for evaluating a patient for MS, including for diagnosing MS, for excluding MS as a diagnosis, and for monitoring the course of disease or efficacy of treatment, including evaluation of immunomodulating therapy. | 2015-02-26 |
20150057182 | METHODS FOR ANALYSIS OF DNA FRAGMENTS - A method of genotyping includes applying a sample solution including a plurality of copies of a sample polynucleotide to an array of sensors. The sample polynucleotide includes a region associated with an allele. The method further includes measuring using a plurality of sensors of the array of sensors a characteristic of the region of the plurality of copies of the sample polynucleotide and determining using a computational circuitry and the measured characteristics a statistical value indicative of the allele. | 2015-02-26 |
20150057183 | METHOD FOR THE DETERMINATION OF THE DNA METHYLATION LEVEL OF A CPG POSITION IN IDENTICAL CELLS WITHIN A TISSUE SAMPLE - Aspects of the present invention relate to the determination of the DNA methylation level at one or more CpG position within cells of a defined type in a tissue sample. This methylation level is deduced from the total DNA methylation level of all cells of the sample and from the content of said cells of interest. In aspects of the invention, the cell content is determined by means of histopatholoy, staining methods, antibodies, expression analysis or DNA methylation analysis. | 2015-02-26 |
20150057184 | CELLULAR MICROARRAYS FOR SCREENING DIFFERENTIATION FACTORS - Provided is a microarray platform for the culture of cells atop combinatorial matrix mixtures; enabling the study of differentiation in response to a multitude of microenvironments in parallel. | 2015-02-26 |
20150057185 | REACTION-BASED FLUORESCENT PROBE FOR SELECTIVE DETECTION OF CARBON MONOXIDE USING METAL-MEDIATED CARBONYLATION - Carbon monoxide (CO) is a member of the gasotransmitter family that includes NO and H | 2015-02-26 |
20150057186 | PHAGE DISPLAY USING COTRANSLATIONAL TRANSLOCATION OF FUSION POLYPEPTIDES - The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation. | 2015-02-26 |
20150057187 | Click Nucleic Acids - Click nucleic acid monomers and polymers containing such monomers are disclosed. The click nucleic acid monomers include an optionally protected thiol moiety, an optionally protected thiol-click acceptor moiety, and an optionally protected nucleobase (NB), which in some examples is an A, G, T, U, or C nucleobase. In some examples, the click nucleic acid monomer includes a N-vinyl thiol acetamide (VTA) backbone. In other examples the click nucleic acid monomer includes a N-vinyl thiol ethylamine (VTE) backbone. Methods of using such polymers, for example in place of naturally occurring nucleic acid polymer applications, such as DNA or RNA, and synthetic nucleic acid polymer applications, such as PNA or morpholino nucleic acids, are also disclosed. | 2015-02-26 |
20150057188 | Quantitative Multiplex Methylation-Specific PCR - Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific PCR (QM-MSP), multiple genes can be quantitatively evaluated from samples usually yielding sufficient DNA for analyses of only 1 or 2 genes. DNA sequences isolated from the sample are simultaneously co-amplified in an initial multiplex round of PCR, and the methylation status of individual hypermethylation-prone gene promoter sequences is then determined separately or in multiplex using a real time PCR round that is methylation status-specific. Within genes of the panel, the level of promoter hypermethylation as well as the incidence of promoter hypermethylation can be determined and the level of genes in the panel can be scored cumulatively. The QM-MSP method is adaptable for high throughput automated technology. | 2015-02-26 |
20150057189 | IN VIVO TRANSDUCTION WITH A CHIMERIC AAV CAPSID PROTEIN - Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided. | 2015-02-26 |
20150057190 | ENCODING OF MICROCARRIERS - Encoded microcarriers, and more specifically microcarriers having codes written on them. Methods for writing the codes on the microcarriers, methods of reading the codes, and methods of using the encoded microcarriers. A preferred method of encoding the microcarriers involves exposing microcarriers containing a bleachable substance to a high spatial resolution light source to bleach the codes on the microcarriers. The encoded microcarriers may be used, for example, as support materials in chemical and biological assays and syntheses. | 2015-02-26 |
20150057191 | IMMUNOGLOBULIN FRAMEWORKS WHICH DEMONSTRATE ENHANCED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND METHODS OF IDENTIFYING SAME - Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability. | 2015-02-26 |
20150057192 | Methods for Dynamic Vector Assembly of DNA Cloning Vector Plasmids - A method for using cloning vector plasmids to produce DNA molecules, such as transgenes, in a single cloning step. The transgenes can be used for the purpose of gene expression or analysis of gene expression. The plasmid cloning vectors are engineered to minimize the amount of manipulation of DNA fragment components by the end user of the vectors and the methods for their use. Transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification. | 2015-02-26 |
20150057193 | ENDOTHELIAL-MONOCYTE ACTIVATING POLYPEPTIDE II (EMAP-II), A BIOMARKER FOR USE IN DIAGNOSIS AND TREATMENT OF BRAIN INJURY - A diagnostic tool and method of diagnosing brain injury and brain injury type (traumatic vs. ischemic) by detecting the level of expression of endothelial monocyte-activating polypeptide II (EMAP II) and comparing to a control. An increase of EMAP II indicates the presence of traumatic brain injury and a decrease of EMAP II indicates the presence of ischemic brain injury. Detection of EMAPII can be done in brain tissue, biofluids such as cerebrospinal fluid or blood (including plasma and serum) | 2015-02-26 |
20150057194 | Integrated Analytical System and Method - An analytical assembly within a unified device structure for integration into an analytical system. The analytical assembly is scalable and includes a plurality of analytical devices, each of which includes a reaction cell, an optical sensor, and at least one optical element positioned in optical communication with both the reaction cell and the sensor and which delivers optical signals from the cell to the sensor. Additional elements are optionally integrated into the analytical assembly. Methods for forming and operating the analytical system are also disclosed. | 2015-02-26 |
20150057195 | Low-Toxicity, Low-Flammability, Environmentally-Safe, Friction Reducer Fluid For Hydraulic Fracturing - Improved hydraulic fracturing compositions are disclosed which help reduce potential negative environmental impact by hydraulic fracturing. The disclosed compositions have flammability and toxicity and are relatively safe for the environment. The compositions may also contain biodegradable components. | 2015-02-26 |
20150057196 | AQUEOUS DOWNHOLE FLUIDS HAVING CHARGED NANO-PARTICLES AND POLYMERS - Charged nanoparticles may be added to an aqueous downhole fluid having polymers therein where the charged nanoparticles may crosslink at least a portion of the polymers. The polymers may be or include, but are not limited to polyacrylamide, xanthan, guar, polyacrylic acid, poly 2-acrylamido-2-methyl-1-propane sulfonic acid (AMPS), polyethylene oxide, polypropylene oxide, or combinations thereof. The polymers may be homopolymers, copolymers, terpolymers, or combinations thereof. The charged nanoparticles may be or include, but are not limited to clay nanoparticles, modified nanoparticles, or combinations thereof. The aqueous downhole fluid may be or include, but is not limited to fracturing fluids, injection fluids, and combinations thereof for performing a fracturing operation, an injection operation, another enhanced oil recovery operation, and the like. | 2015-02-26 |
20150057197 | Use of Oil-Soluble Surfactants as Breaker Enhancers for VES-Gelled Fluids - Fluids viscosified with viscoelastic surfactants (VESs) may have their viscosities reduced (gels broken) by the direct or indirect action of an internal breaker composition that contains at least one mineral oil, at least one polyalphaolefin oil, at least one saturated fatty acid and/or at least one unsaturated fatty acid. The internal breaker may initially be dispersed oil droplets in an internal, discontinuous phase of the fluid. In one non-limiting embodiment, the internal breaker, e.g. mineral oil, is added to the fluid after it has been substantially gelled. An oil-soluble surfactant is present to enhance or accelerate the reduction of viscosity of the gelled aqueous fluid. | 2015-02-26 |
20150057198 | Proppant Material Incorporating Fly Ash and Method of Manufacture - A relatively low density, high strength round proppant material having (i) a round core made of a sintered mixture of fly ash and clay or, in some instances, fly ash, clay, and bauxite; and (ii) an outer shell made of sintered bauxite, and a method of making the same. | 2015-02-26 |
20150057199 | Composition for Sliding Member - A composition for sliding member includes a binder resin, a solid lubricant, and an epoxy modified silicone oil having an epoxy group at both ends or at one end thereof. A weight ratio of the binder resin and the epoxy modified silicone oil is 97:3 to 75:25. | 2015-02-26 |
20150057200 | LUBRICANT COMPOSITION FOR INTERNAL COMBUSTION ENGINE OIL - The lubricating oil composition for internal combustion engines of the present invention contains a base oil, a thioheterocyclic compound represented by the following formula (I) | 2015-02-26 |
20150057201 | LUBRICATING THERMOPLASTIC RESIN COMPOSITION AND FORMED ARTICLE THEREOF - [Object] To provide lubricating thermoplastic resin compositions that can give formed articles exhibiting excellent lubricating properties and surface appearance and maintaining the lubricating properties permanently. | 2015-02-26 |
20150057202 | LUBRICATING OIL COMPOSITION FOR TRANSMISSIONS - The present invention provides a lubricating oil composition for transmissions which is improved in fuel saving properties and has excellent metal fatigue prevention properties and heat resistance. The lubricating oil composition comprises (A) a mineral base oil having a 100° C. kinematic viscosity of 1.5 mm | 2015-02-26 |
20150057203 | LUBRICATING OIL COMPOSITION AND DEVICE USING SAME - A lubricating oil composition contains a base oil containing a compound (A) and a compound (B) below and a compound (C). The lubricating oil composition exhibits a kinematic viscosity at 40 degrees C. in a range of 20 mm | 2015-02-26 |
20150057204 | Maleanized Ester Derivatives - This disclosed invention relates to a maleinated ester derivative derived from an unsaturated linear aliphatic carboxylic acid methyl ester, maleic anhydride, and a monohydric alcohol. Lubricants and functional fluids containing the maleinated esters are disclosed. | 2015-02-26 |
20150057205 | HIGHLY AROMATIC BASE OIL AND METHOD FOR PRODUCING HIGHLY AROMATIC BASE OIL - A method for producing a highly aromatic base oil of the present invention includes a step of hydrorefining a clarified oil to obtain a highly aromatic base oil having an aromatic content of 50% by mass or more determined by a column chromatography analysis method. The step of hydrorefining a clarified oil is preferably performed under conditions of a hydrogen pressure of 5.0 to 20.0 MPa, a temperature of 280 to 400° C., a hydrogen oil ratio of 300 to 750 NL/L, and a space velocity of 0.3 to 2.0 h | 2015-02-26 |
20150057206 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS - The present invention relates to novel pyrimidine derivatives and their use in perfume compositions. The novel pyrimidine derivatives of the present invention are represented by the following formula: | 2015-02-26 |
20150057207 | NOVEL ORGANOLEPTIC COMPOUNDS - The present invention relates to novel compounds and their use as fragrance materials. | 2015-02-26 |
20150057208 | TEAR FREE BABY CLEANSER - The present application directed to a unique combination of surfactants in concentrated form. In particular certain combinations of alkyl polyglucosides and polyglyceryl fatty acid esters when combined yield a cleansing concentrate which can be diluted to form tear free or mild cleanser. | 2015-02-26 |
20150057209 | ABRASIVE GRAIN, POLISHER, AND PRODUCTION METHOD OF ABRASIVE GRAIN - An abrasive grain includes a granular porous body in which many primary grains are bonded with each other partially, and in a state where pores are formed, and a functionalizing material which is constituted of a material which is different from the primary grains is contained within the abrasive grain. | 2015-02-26 |
20150057210 | SOLUBLE UNIT DOSE ARTICLES COMPRISING A CATIONIC POLYMER - The need for a stable, quick dissolving unit dose article delivering good fabric care benefit is met by combining a cationic polymer with a fatty acid or salt in a non-aqueous composition, that is comprised within a water-soluble or dispersible film. By combining the cationic polymer with the fatty acid, the cationic polymer is prevented from reducing the solubility of the encapsulating film. | 2015-02-26 |
20150057211 | COMPOSITIONS COMPRISING ALKOXYLATED POLYAMINES HAVING LOW MELTING POINTS - The present invention relates to compositions comprising water-soluble alkoxylated polyamines with a low melting point. More specifically, the present invention relates to compositions comprising water-soluble alkoxylated polyamines having an inner polyethylene oxide block comprising 5 to 18 polyethylene oxide units, a middle polyalkylene oxide block comprising 1 to 5 polyalkylene oxide units and an outer polyethylene oxide block comprising 2 to 14 polyethylene oxide units. | 2015-02-26 |
20150057212 | CLEANING COMPOSITIONS CONTAINING A POLYETHERAMINE - The present invention relates generally to cleaning compositions and, more specifically, to cleaning compositions containing a polyetheramine that is suitable for removal of stains from soiled materials. | 2015-02-26 |
20150057213 | COMPOSITIONS COMPRISING ALKOXYLATED POLYALKYLENEIMINES HAVING LOW MELTING POINTS - The present invention relates to compositions comprising water-soluble alkoxylated polyalkyleneimines with a low melting point. More specifically, the present invention relates to compositions comprising water-soluble alkoxylated polyalkyleneimines having an inner polyethylene oxide block comprising 5 to 18 polyethylene oxide units, a middle polyalkylene oxide block comprising 1 to 5 polyalkylene oxide units and an outer polyethylene oxide block comprising 2 to 14 polyethylene oxide units. | 2015-02-26 |
20150057214 | EMULSION COMPOSITIONS AND A METHOD FOR SELECTING SURFACTANTS - A method for preparing a microemulsion is disclosed which employs a method based upon identification of the phase behavior of a plurality of components comprising the microemulsion. Further disclosed is a microemulsion composition comprising a first component, coupling agent, and surfactant. | 2015-02-26 |
20150057215 | SOAP KIT FOR ASSSEMBLY - A soap kit that includes a plurality of soap pieces for assembly. Each soap piece is configured to engage with a geometrically conforming portion of at least another complementary soap piece, such that the soap pieces can be collectively arranged to form a unified integrated soap unit. The soap pieces may be engaged with one another while in a wet state to facilitate their adhesion. The soap pieces may then be transitioned from a wet state to a dry state to reinforce the adhesion and facilitate solidification of the soap unit. The integrated soap unit may depict a representation of an image or constitute a representation of an object. | 2015-02-26 |
20150057216 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS - The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on Angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided. | 2015-02-26 |
20150057217 | SHORT DESIGNED PEPTIDES POSSESSING SELECTIVE ACTIONS AGAINST BACTERIA AND CANCER CELLS - The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below | 2015-02-26 |
20150057218 | INHIBITORS OF HCV NS5A - Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C. | 2015-02-26 |
20150057219 | REVERSIBLE PEGYLATED DRUGS - Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety. | 2015-02-26 |
20150057220 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS - Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer. | 2015-02-26 |
20150057221 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L | 2015-02-26 |
20150057222 | METHODS OF TREATING CARTILAGE DEFECTS USING A SOLUBLE MORPHOGENIC PROTEIN COMPLEX - The present invention provides methods of repairing and regenerating cartilage tissue using a soluble morphogenic protein complex comprising (a) a morphogenic protein; and (b) a morphogenic protein pro region isolated from a morphogenic protein, or a conservative substitution variant or a fragment of said pro region, wherein said pro region or variant or fragment is noncovalently linked to the morphogenic protein, and wherein said complex is more soluble in an aqueous solvent than said morphogenic protein alone. | 2015-02-26 |
20150057223 | HIGH ACTIVITY GROWTH FACTOR MUTANTS - The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity. | 2015-02-26 |
20150057224 | METHODS FOR CHRONIC PAIN MANAGEMENT AND TREATMENT USING HCG - A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonodotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug. | 2015-02-26 |
20150057225 | Method and Composition for Synchronizing Time of Insemination - Methods and compositions for synchronizing the time of insemination in swine are described. More particularly, methods are described for synchronizing the time of insemination by administration of a composition comprising a hormone, wherein the swine is inseminated only one time after administration of the hormone, and wherein there is no heat detection. | 2015-02-26 |
20150057226 | METHOD FOR TREATMENT OF LABOR ARREST - The present invention refers to the use of certain sulfated glycosaminoglycans for treatment of labor arrest. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with an agent capable of promoting myometrial contractions of the uterus and thereby re-establish effective labor. | 2015-02-26 |
20150057227 | COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS - The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered. | 2015-02-26 |
20150057228 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2015-02-26 |
20150057229 | METHOD OF TREATING BONE DISORDERS USING TSG-6 - A method for inhibiting cartilage degradation comprising administering to a subject a therapeutically effective amount of a polypeptide comprising or consisting of a Link_TSG6 polypeptide is disclosed | 2015-02-26 |
20150057230 | BIOTIN-CONJUGATED HEXAPEPTIDE-2 DERIVATIVE AND USE THEREOF - The present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof and use thereof. More particularly, the present invention relates to a biotin-conjugated hexapeptide-2 derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, a composition including the same as an active ingredient, and a method for improving wrinkles and inhibiting skin aging using the same. | 2015-02-26 |
20150057231 | Use of Engrailed Proteins for Increasing Dopamine Synthesis by Dopaminergic Neurons - The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons | 2015-02-26 |
20150057232 | Anti-Inflammatory Composition for Modulating the Cell Response of Neutrophils and Eosinophils - The present invention relates to an anti-inflammatory composition intended for humans and animals for modulating the cell response of the neutrophils and of eosinophils. | 2015-02-26 |
20150057233 | CALCINEURIN INHIBITORS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS - The present invention relates to a calcineurin inhibitor for use in the treatment of a lesional vestibular disorder. | 2015-02-26 |
20150057234 | HYDRATE OF CYCLOPEPTIDE COMPOUND AS WELL AS PREPARATION METHOD AND USE THEREOF - Disclosed is a hydrate of a compound as shown in Formula I. In formula I, R represents H or a cation capable of forming a pharmaceutically acceptable salt. The mass percentage of water in the hydrate is more than 8%. The hydrate has good stability. Moreover, disclosed are a preparation method and a use thereof. | 2015-02-26 |
20150057235 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer. | 2015-02-26 |
20150057236 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME - Sirt5, a mitochondrial Sirtuin, has been identified herein as an efficient demalonylase and desuccinylase. Disclosed herein are assays to identify Sirt5 modulators based on this robust enzymatic activity. Sirt5-specific modulators can be used study the biological function of Sirt5 and to target Sirt5 activities in treating human diseases. | 2015-02-26 |
20150057237 | MODULAR BIORESORBABLE OR BIOMEDICAL, BIOLOGICALLY ACTIVE SUPRAMOLECULAR MATERIALS - The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or biomedical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies. | 2015-02-26 |
20150057238 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 2015-02-26 |
20150057239 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS - A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition. | 2015-02-26 |
20150057240 | C-TERMINAL HSP90 INHIBITORS - Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy. | 2015-02-26 |
20150057241 | FORMULATIONS OF AMINOGLYCOSIDES AND FOSFOMYCIN IN A COMBINATION HAVING IMPROVED CHEMICAL PROPERTIES - The present invention is synergistic antibiotic compositions having pH adjusted profiles for manufacturing combination, and administration, particularly for patients at risk or suffering from ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic compositions containing fosfomycin and aminoglycosides having individually predetermined and selected pH ranges are manufactured and stored for in combination prior to aerosolization, preferably with a specially designed in-line nebulizer attached to a ventilator. | 2015-02-26 |
20150057242 | FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 2015-02-26 |
20150057243 | Compositions and Methods for the Inhibition of Methyltransferases - Methods and compositions disclosed herein relate to detecting, analyzing, isolating and inhibiting methyltransferases, methyltransferase substrates, S-adenosyl-methionine-binding proteins and RNA, including for the treatment of disease. | 2015-02-26 |
20150057244 | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASE - This invention provides a method of preventing or treating a dermatologic condition including, inter alia, psoriasis, contact dermatitis, and atopic dermatitis, in a subject, the method includes the step of administering to said subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, in an amount effective to treat the subject suffering from a dermatologic condition. | 2015-02-26 |
20150057245 | USE OF LIPID CONJUGATES IN THE TREATMENT OF INFLAMMATORY DISORDERS - This invention provides for the use of compounds represented by the structure of the general formula (A): | 2015-02-26 |
20150057246 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R | 2015-02-26 |
20150057247 | PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS - Provided herein are compounds of the formula (I): | 2015-02-26 |
20150057248 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS - Embodiments of the invention are directed to compounds that are positive allosteric modulators of AMPA receptors. | 2015-02-26 |
20150057249 | Vesicular Formulations - The present invention relates to vesicular formulations for the treatment of rosacea. It also relates to a method of treating rosacea comprising administering a vesicular formulation according to the invention. | 2015-02-26 |
20150057250 | INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS - Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form | 2015-02-26 |
20150057251 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN - Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation. | 2015-02-26 |
20150057252 | PHARMACEUTICAL COMPOSITION AND USE OF DIETHYL (2-CYANOETHYL)PHOSPHONATE - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and diethyl(2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering diethyl(2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 2015-02-26 |
20150057253 | ALKYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2015-02-26 |
20150057254 | ONCE DAILY FORMULATIONS OF TETRACYCLINES - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 2015-02-26 |
20150057255 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS - The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent. | 2015-02-26 |
20150057256 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR - The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with β2 adrenergic receptor activity and a process for preparing such polymorphic crystal forms. | 2015-02-26 |
20150057257 | ISOXAZOLIDINE DERIVATIVES - Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction. | 2015-02-26 |
20150057258 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES - The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation. | 2015-02-26 |